A Phase 3 Open-Label, Randomized Study of PDS0101 and Pembrolizumab vs Pembrolizumab Alone in First-Line Treatment of Unresectable Recurrent and/or Metastatic HPV16+ Head and Neck Squamous Cell Carcinoma
NCT06790966 · ACTIVE NOT RECRUITING · Phase 3
We track 1 ClinicalTrials.gov studies led by Pds Biotechnology Corp. The portfolio skews toward Phase 3 (1 trials).
1 clinical trials sponsored by Pds Biotechnology Corp.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 3 | 1 | 100% |
Pds Biotechnology Corp currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 3.
Pds Biotechnology Corp conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.